Clinical trials are carefully designed research studies conducted in humans to evaluate the safety, efficacy, and overall benefit of medical interventions such as drugs, biologics,

Enforcement discretion means that a regulatory agency like the FDA (U.S. Food and Drug Administration) chooses not to enforce certain rules or regulations under specific

Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood

Chen H, Liu S, Gao S, Shi H, Yan Y, Xu Y, Fang J, Wang W, Chen H, Liu Z. Pharmacovigilance analysis of neurological adverse

Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are

by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds

This academic article, “Nutritional priorities to support GLP‐1 therapy for obesity,” is a joint advisory from several prominent American health organizations. It examines the use of GLP-1 receptor

PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for

Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41,

Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific

This meta-analysis examines the impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RAs), medications used for obesity and diabetes, on the mental health and quality of

May 23, 2025Stat + by Katie Palmer https://ro.co/ https://lifemd.com/ Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the

This research paper explores the impact of amino acid restriction on weight loss, focusing on the unique effects of cysteine deficiency. The study demonstrates that cysteine restriction in mice, particularly those with compromised

This abstract evaluates a multi-cancer early detection (MCED) blood test specifically designed for individuals with obesity, a group at higher risk for several cancers often without standard screening.

What You Should Know:  – Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans.  – These expanded offerings are

The sources discuss Fractyl Health’s Rejuva GLP-1 gene therapy platform, highlighting preclinical data presented at ASGCT 2025 for its candidate RJVA-001. This research indicates that a single dose

ChatGPTMay 26, 2025 Fatigue or low energy is a commonly reported side effect among users of GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound),

WSJ article discusses the growing trend of microdosing GLP-1 medications, like Ozempic and Zepbound, which are primarily used for weight loss and diabetes management. Some individuals

This scientific article examines the connection between aging and metabolic changes in humans. It focuses on age-related alterations in adipose tissue, muscle, and liver, noting how sedentary habits worsen these

Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort studyWolff Sagy, Yael et al. eClinicalMedicine,

There is a significant burden of chronic diseases in the United States, comparing its rates to other developed nations. One source from the Peterson-KFF Health System Tracker

This systematic review and meta-analysis investigated the rate of weight regain after people stopped using GLP-1 receptor agonists (GLP-1 RAs) for weight management. The researchers identified relevant studies and analyzed the weight loss achieved

Global burden and strength of evidence for 88 risk factors in204 countries and 811 subnational locations, 1990–2021 : a systematic analysis for the Global Burden

ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERYFebruary 14, 2025By Adare Pharmaceuticals Obesity is a significant global health challenge that requires lifestyle changes

This talk at the discuss the development of new medications designed to address muscle loss that can occur alongside weight loss achieved with GLP-1 receptor agonists like semaglutide and tirzepatide. While

According to an article in Medscape Medical News, a study presented at the AACE 2025 conference indicates that individuals treated for obesity using semaglutide (Wegovy) may experience

Are you wanting to save some money? Discouraged by the high price of the GLP-1 drugs from the big pharmaceutical companies and the compounding pharmacies?

Experts warn that current methods of making the peptide drugs are environmentally unfriendly April 28, 2024 by Aayushi Pratap Chemical & Engineering News, Volume 102,

Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025 Mar;49(3):452-463. doi: 10.1038/s41366-024-01599-z.

This academic paper examines whether tailoring anti-obesity medication based on specific patient characteristics, or “phenotypes,” improves weight loss outcomes compared to standard treatment. Researchers classified

This paper describes a phase 3b clinical trial comparing tirzepatide and semaglutide for weight management in adults with obesity but without diabetes. The SURMOUNT-5 trial randomly assigned participants to receive either

The common belief is that as GLP-1s become more popular, that will stimulate competition in generics and new drug development. This is all good, right?

Several companies and research groups are actively exploring implantable drug delivery systems for GLP-1 receptor agonists (GLP-1 RAs), aiming to improve patient adherence, convenience, and

March 14, 2025 Hunter Gibble T, Chinthammit C, Ward JM, Cappell K, Sedgley R, Bonafede M, Liao B, Hankosky ER. Real-world use of tirzepatide among

Gutgesell RM, Khalil A, Liskiewicz A, Maity-Kumar G, Novikoff A, Grandl G, Liskiewicz D, Coupland C, Karaoglu E, Akindehin S, Castelino R, Curion F, Liu

January 16, 2025Thyroid Vol 35, No. 1 This research article investigates the potential link between glucagon-like peptide 1 receptor agonists (GLP1-RAs), medications used for type 2

Released: January 7, 2025Level 1 GuidanceDraft This draft guidance document from the U.S. Food and Drug Administration (FDA) outlines recommendations for the development of drugs and biological products intended

by Daniel J Drucker Nature Reviews Drug Discovery Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025 Apr 25. doi:

The company’s health services division Evernorth is unveiling new programs in a reliable growth area: assuaging payer concerns around GLP-1 coverage. Dive Brief: This article

That’s the question researchers aim to answer in a new, first-of-its-kind, clinical trial in North Texas By Bianca Castro • Published April 30, 2025 • Updated on April 30, 2025 at 10:52 pm